Ann: Regeneus receives upfront payment of US$5.5m from AGC, page-2

Brilliant news!


Regeneus Ltd (ASX: RGS), a clinical stage regenerative medicine company, today announced it has received
US$5.5m from AGC as an upfront payment for the exclusive rights to manufacture Progenza under the terms
of the collaboration and licence announced on 29 December 2016.
Regeneus is expected to receive a further US$11m in specific development and approval milestone
payments. Regeneus will be entitled, through its 50 per cent interest in Regeneus Japan, to its share of upfront
licence fees, milestone payments and royalties from sub licensing the development and commercialisation of
Progenza for osteoarthritis and all other clinical indications in Japan. AGC will be responsible for funding the
manufacture of Progenza for the proposed Phase 2 trial for osteoarthritis in Japan under specific conditions.